Page last updated: 2024-08-23

lovastatin and Neoplasms

lovastatin has been researched along with Neoplasms in 40 studies

Research

Studies (40)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (10.00)	18.2507
2000's	20 (50.00)	29.6817
2010's	13 (32.50)	24.3611
2020's	3 (7.50)	2.80

Authors

Authors	Studies
Blanco, FJ; Cossío, FP; Dejaegere, A; Lopez, X; Martin, E; Mendoza, L; Pantoja-Uceda, D; San Sebastián, E; Sirockin, F; Stote, RH; Valcárcel, M; Vara, Y; Vidal-Vanaclocha, F; Zimmerman, T; Zubia, A	1
Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L	1
Hsieh, CL; Hsu, MJ; Huang, CC; Huang, WJ; Lin, RK; Lin, YF; Wang, CY	1
Ben-David, Y; Gajendran, B; Gao, J; Hu, A; Hu, J; Kuang, Y; Liu, W; Sheng, D; Wang, C; Xiao, X; Yu, F; Yu, K; Zacksenhaus, E	1
Rao, PS; Rao, US	1
Chen, X; Ji, X; Shang, J; Wei, Y; Xie, L; Zhang, C; Zhang, Q; Zhu, G	1
Carter, LM; Durack, JC; Edwards, KJ; Janjigian, YY; Lewis, JS; Pereira, PMR; Pourat, J; Ragupathi, A; Sharma, SK	1
Aschmann, HE; Kaufmann, M; Puhan, MA; Yebyo, HG	1
Geley, S; Hengst, L; Kullmann, M; Masuccio, A; Ploner, C; Vosper, J	1
Gerner, C; Grunt, T; Haider, F; Karlic, H; Proestling, K; Thaler, R; Varga, F	1
Aristizabal Prada, ET; Auernhammer, CJ; Göke, B; Grossman, A; Korbonits, M; Maurer, J; Nölting, S; Reuther, C; Spöttl, G; Young, K	1
Chou, RC; Langan, TJ; Li, V; Rodgers, KR	1
Xiao, H; Yang, CS	1
Bil, J; Golab, J; Jakobisiak, M; Nowis, D; Zapala, L	1
Mitrofan, LM; Mönkkönen, J; Pelkonen, J	1
Inouye, K; Ishikawa, T; Mizuki, E; Okumura, S; Saitoh, H	1
Bil, J; Golab, J; Issat, T; Jakobisiak, M; Nowis, D; Winiarska, M	1
Hohl, RJ; Holstein, SA; Kuder, CH; Tong, H	1
Brower, V	1
Andela, VB; O'Keefe, RJ; Pirri, M; Puzas, EJ; Rosenblatt, JD; Rosier, RN; Schwarz, EM	1
Dippold, W; Fritz, G; Kaina, B; Kleinert, H; Nübel, T	1
Dippold, W; Fritz, G; Kaina, B; Nübel, T	1
Elson, CE; Mo, H	1
Clamon, GH; Hohl, RJ; Holstein, SA; Knapp, HR; Murry, DJ	1
Giri, S; Rattan, R; Singh, AK; Singh, I	1
Kenna, T; Mattarollo, SR; Nicol, AJ; Nieda, M	1
Bravo, L; Gupta, J; McAnally, JA; Mo, H; Sodhani, S	1
Alsheikh-Ali, AA; Han, H; Karas, RH; Maddukuri, PV	1
Chan, J; Flick, ED; Friedman, GD; Habel, LA; Quesenberry, CP; Udaltsova, N	1
Brophy, MT; Farwell, WR; Fiore, LD; Gaziano, JM; Lawler, EV; Lew, RA; Scranton, RE	1
Weitberg, AB	1
Buquet-Fagot, C; Lallemand, F; Mester, J; Montagne, MN	1
Cooper, MR; Figg, WD; Hohl, RJ; Liang, B; Myers, CE; Patronas, N; Reed, E; Samid, D; Thibault, A; Tompkins, AC; Trepel, J; Venzon, DJ	1
Benzaquen, M; Dimitroulakos, J; Freedman, MH; Kamel-Reid, S; Moore, MJ; Penn, LZ; Ye, LY; Yeger, H	1
Davignon, J; Mabile, L	1
Garrett, IR; Gutierrez, G; Mundy, GR	1
Dimitroulakos, J; Minden, MD; Penn, LZ; Tan, MM; Wong, WW; Xia, Z	1
Platts, J	1
Buchwald, H	1
Cox, AD; Der, CJ; Kato, K; Khosravi-Far, R	1

Reviews

10 review(s) available for lovastatin and Neoplasms

Article	Year
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nature cell biology, 2015, Volume: 17, Issue:11 Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction	2015
An overview on the biological activity and anti-cancer mechanism of lovastatin. Cellular signalling, 2021, Volume: 87 Topics: Apoptosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Neoplasms	2021
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. American heart journal, 2019, Volume: 210 Topics: Atorvastatin; Cardiovascular Diseases; Cause of Death; Chemical and Drug Induced Liver Injury; Double-Blind Method; Fluvastatin; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Lovastatin; Middle Aged; Muscular Diseases; Nausea; Neoplasms; Network Meta-Analysis; Placebos; Pravastatin; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Withholding Treatment	2019
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention. International journal of cancer, 2008, Sep-01, Volume: 123, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Meta-Analysis as Topic; Neoplasms; Pravastatin; Pyrazoles; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Sulfonamides; Sulindac	2008
The mevalonate synthesis pathway as a therapeutic target in cancer. Clinical orthopaedics and related research, 2003, Issue:415 Suppl Topics: Acute-Phase Proteins; Alendronate; Alkyl and Aryl Transferases; Animals; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Farnesyltranstransferase; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mevalonic Acid; Mice; Neoplasms; Polyisoprenyl Phosphates; Tumor Cells, Cultured	2003
Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Experimental biology and medicine (Maywood, N.J.), 2004, Volume: 229, Issue:7 Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Cell Cycle; Cell Division; Clinical Trials as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mevalonic Acid; Neoplasms; Protein Processing, Post-Translational; Terpenes	2004
Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. Journal of the American College of Cardiology, 2007, Jul-31, Volume: 50, Issue:5 Topics: Chemical and Drug Induced Liver Injury; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Liver Diseases; Lovastatin; Neoplasms; Pravastatin; Rhabdomyolysis; Simvastatin	2007
[Mechanisms of action of statins and their pleiotropic effects]. Annales d'endocrinologie, 2001, Volume: 62, Issue:1 Pt 2 Topics: Arteriosclerosis; Cell Division; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lovastatin; Neoplasms; Osteoporosis	2001
Statins and bone formation. Current pharmaceutical design, 2001, Volume: 7, Issue:8 Topics: Animals; Bone Development; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lovastatin; Neoplasms; Nitric Oxide Synthase; Pyridines; Simvastatin	2001
Protein prenylation: key to ras function and cancer intervention? Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research, 1992, Volume: 3, Issue:7 Topics: Alkyl and Aryl Transferases; Amino Acid Sequence; Fungal Proteins; GTP-Binding Proteins; Humans; Lovastatin; Mevalonic Acid; Molecular Sequence Data; Neoplasm Proteins; Neoplasms; Polyisoprenyl Phosphates; Protein Processing, Post-Translational; Proto-Oncogene Proteins p21(ras); ras Proteins; Saccharomyces cerevisiae; Transferases	1992

Trials

2 trial(s) available for lovastatin and Neoplasms

Article	Year
Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:2 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Dose-Response Relationship, Drug; Female; Humans; Lovastatin; Male; Middle Aged; Neoplasms	2006
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 1996, Volume: 2, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Neoplasms; Ubiquinone	1996

Other Studies

28 other study(ies) available for lovastatin and Neoplasms

Article	Year
Design, synthesis, and functional evaluation of leukocyte function associated antigen-1 antagonists in early and late stages of cancer development. Journal of medicinal chemistry, 2013, Feb-14, Volume: 56, Issue:3 Topics: Cell Line, Tumor; Drug Design; Humans; Lymphocyte Function-Associated Antigen-1; Models, Molecular; Neoplasms; Structure-Activity Relationship	2013
Synthesis and biological evaluation of lovastatin-derived aliphatic hydroxamates that induce reactive oxygen species. Bioorganic & medicinal chemistry letters, 2016, 11-15, Volume: 26, Issue:22 Topics: Anticholesteremic Agents; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Humans; Hydroxamic Acids; Lovastatin; Neoplasms; Reactive Oxygen Species	2016
Lovastatin inhibits erythroleukemia progression through KLF2-mediated suppression of MAPK/ERK signaling. BMC cancer, 2023, Apr-04, Volume: 23, Issue:1 Topics: Animals; Apoptosis; Cholesterol; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kruppel-Like Transcription Factors; Leukemia, Erythroblastic, Acute; Lovastatin; Mice; Neoplasms	2023
Statins decrease the expression of c-Myc protein in cancer cell lines. Molecular and cellular biochemistry, 2021, Volume: 476, Issue:2 Topics: Atorvastatin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mevalonic Acid; Neoplasms; Proto-Oncogene Proteins c-myc; Simvastatin	2021
Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. Nature communications, 2018, 12-03, Volume: 9, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Caveolin 1; Cell Line, Tumor; Cell Membrane; Endocytosis; Female; Humans; Lovastatin; MCF-7 Cells; Mice, Nude; Neoplasms; Protein Binding; Receptor, ErbB-2; RNA Interference; Trastuzumab; Treatment Outcome; Xenograft Model Antitumor Assays	2018
Statin-induced depletion of geranylgeranyl pyrophosphate inhibits cell proliferation by a novel pathway of Skp2 degradation. Oncotarget, 2015, Feb-20, Volume: 6, Issue:5 Topics: Alkyl and Aryl Transferases; Animals; Antigens, CD; Antineoplastic Agents; Cadherins; Cdh1 Proteins; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Genes, APC; HeLa Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Neoplasms; NIH 3T3 Cells; Polyisoprenyl Phosphates; Proteasome Endopeptidase Complex; Proteolysis; S-Phase Kinase-Associated Proteins; Signal Transduction; Time Factors; Transfection; U937 Cells	2015
Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells. Cancer genetics, 2015, Volume: 208, Issue:5 Topics: Antineoplastic Agents; Cell Line, Tumor; Diphosphonates; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Down-Regulation; Epigenesis, Genetic; Fatty Acids; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Ibandronic Acid; Lovastatin; Mevalonic Acid; MicroRNAs; NADP; Neoplasms; Protein Processing, Post-Translational; Simvastatin; Vitamin D	2015
Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways. PloS one, 2015, Volume: 10, Issue:12 Topics: Animals; Drug Synergism; ErbB Receptors; Everolimus; Hep G2 Cells; Humans; Lovastatin; MAP Kinase Signaling System; Mice; Mice, Knockout; Neoplasms; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa	2015
Differential and kinetic effects of cell cycle inhibitors on neoplastic and primary astrocytes. Cell cycle (Georgetown, Tex.), 2016, Volume: 15, Issue:19 Topics: Animals; Astrocytes; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; DNA; Hydroxyurea; Kinetics; Lovastatin; Neoplasms; Rats, Sprague-Dawley; Serum	2016
Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro. Cancer letters, 2010, Feb-01, Volume: 288, Issue:1 Topics: Animals; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Mice; Myocytes, Cardiac; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Prenylation; Pyridines; Pyrroles; Rats; Sorafenib; Sunitinib	2010
The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro. Bone, 2009, Volume: 45, Issue:6 Topics: Adenosine Triphosphate; Apoptosis; Cell Line, Tumor; Diphosphonates; Diterpenes; Drug Resistance, Neoplasm; Hemiterpenes; Humans; Imidazoles; Lovastatin; Membrane Potential, Mitochondrial; Neoplasms; Organophosphorus Compounds; Zoledronic Acid	2009
Mode of action of parasporin-4, a cytocidal protein from Bacillus thuringiensis. Biochimica et biophysica acta, 2011, Volume: 1808, Issue:6 Topics: Anticholesteremic Agents; Bacillus thuringiensis; Bacterial Proteins; Caco-2 Cells; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Membrane; Cell Size; Cell Survival; Cholesterol; Circular Dichroism; Dose-Response Relationship, Drug; Endotoxins; Enzyme Activation; Flow Cytometry; HeLa Cells; Humans; K562 Cells; L-Lactate Dehydrogenase; Lovastatin; Microscopy, Phase-Contrast; Neoplasms; Protein Binding; Protein Multimerization	2011
Antitumor effects of the combination of cholesterol reducing drugs. Oncology reports, 2011, Volume: 26, Issue:1 Topics: Animals; Anticholesteremic Agents; Antineoplastic Agents; Berberine; Cell Cycle; Cell Line, Tumor; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mevalonic Acid; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplasms	2011
Pleiotropic effects of a schweinfurthin on isoprenoid homeostasis. Lipids, 2011, Volume: 46, Issue:10 Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Synergism; Humans; Lovastatin; Neoplasms; Polyisoprenyl Phosphates; Prenylation; Sesquiterpenes; Stilbenes; Terpenes	2011
Of cancer and cholesterol: studies elucidate anticancer mechanisms of statins. Journal of the National Cancer Institute, 2003, Jun-18, Volume: 95, Issue:12 Topics: Animals; Anticarcinogenic Agents; Anticholesteremic Agents; Breast Neoplasms; Canada; Cell Cycle; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Microfilament Proteins; Multienzyme Complexes; Muscle Proteins; Neoplasms; Proteasome Endopeptidase Complex; Pyridines; Signal Transduction	2003
Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2004, Volume: 18, Issue:1 Topics: Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cells, Cultured; E-Selectin; Endothelium, Vascular; Humans; Lovastatin; Neoplasms; rho GTP-Binding Proteins; Signal Transduction; Transcription, Genetic; Tumor Necrosis Factor-alpha	2004
Ionizing radiation-induced E-selectin gene expression and tumor cell adhesion is inhibited by lovastatin and all-trans retinoic acid. Carcinogenesis, 2004, Volume: 25, Issue:8 Topics: Blotting, Western; Cell Adhesion; Cell Line, Tumor; Cells, Cultured; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; E-Selectin; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Lovastatin; Neoplasms; NF-kappa B; Promoter Regions, Genetic; Radiation, Ionizing; Reverse Transcriptase Polymerase Chain Reaction; rho GTP-Binding Proteins; RNA, Messenger; Transcriptional Activation; Tretinoin; Tumor Necrosis Factor-alpha	2004
Rho/ROCK pathway as a target of tumor therapy. Journal of neuroscience research, 2006, Feb-01, Volume: 83, Issue:2 Topics: Amides; Animals; Antineoplastic Agents; Apoptosis; Blotting, Southern; Blotting, Western; Caspases; Cell Survival; Disease Models, Animal; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Flow Cytometry; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Intracellular Signaling Peptides and Proteins; Lovastatin; Male; Mevalonic Acid; Mice; Neoplasms; Neoplasms, Experimental; Polyisoprenyl Phosphates; Protein Serine-Threonine Kinases; Pyridines; Rats; Rats, Wistar; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured	2006
Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity. Cancer immunology, immunotherapy : CII, 2007, Volume: 56, Issue:8 Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Burkitt Lymphoma; Carcinoma; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Concanavalin A; Cytotoxicity, Immunologic; Diphosphonates; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Genes, T-Cell Receptor delta; Genes, T-Cell Receptor gamma; Humans; Imidazoles; Interferon-gamma; Lovastatin; Lung Neoplasms; Male; Membrane Glycoproteins; Neoplasms; Perforin; Pore Forming Cytotoxic Proteins; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Urinary Bladder Neoplasms; Vincristine; Zoledronic Acid	2007
Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo. Experimental biology and medicine (Maywood, N.J.), 2007, Volume: 232, Issue:4 Topics: Animals; Antioxidants; Cardiovascular Diseases; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Activation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mevalonic Acid; Mice; Neoplasm Proteins; Neoplasms; Terpenes; Tocotrienols	2007
Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:1 Topics: California; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Neoplasms; Risk; Risk Factors; Simvastatin	2008
The association between statins and cancer incidence in a veterans population. Journal of the National Cancer Institute, 2008, Jan-16, Volume: 100, Issue:2 Topics: Adult; Aged; Anticholesteremic Agents; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Middle Aged; Multivariate Analysis; Neoplasms; Odds Ratio; Pravastatin; Proportional Hazards Models; Research Design; Retrospective Studies; Simvastatin; United States; Veterans	2008
The antioxidant effect of lovastatin on phagocyte-induced DNA damage: implications for cancer prevention. Journal of experimental & clinical cancer research : CR, 2007, Volume: 26, Issue:4 Topics: Anticarcinogenic Agents; Antioxidants; DNA Damage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Neoplasms; Phagocytes; Reactive Oxygen Species	2007
Effects of olomoucine, a selective inhibitor of cyclin-dependent kinases, on cell cycle progression in human cancer cell lines. Anti-cancer drugs, 1997, Volume: 8, Issue:6 Topics: Cell Cycle; Cell Division; Cyclin-Dependent Kinases; Enzyme Inhibitors; Humans; Kinetin; Lovastatin; Neoplasms; Purines; Retinoblastoma Protein; Thymidine; Thymidine Kinase; Tritium; Tumor Cells, Cultured	1997
Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:1 Topics: Adult; Antineoplastic Agents; Apoptosis; Child; Chromatography, High Pressure Liquid; Female; Flow Cytometry; Formazans; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mass Spectrometry; Mevalonic Acid; Microscopy, Electron; Neoplasms; Tetrazolium Salts; Tumor Cells, Cultured	2001
Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:7 Topics: Acute Disease; Apoptosis; Atorvastatin; Cell Division; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Leukemia, Myeloid; Lovastatin; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyridines; Pyrroles; Sensitivity and Specificity; Tumor Cells, Cultured	2001
Therapy and clinical trials. Current opinion in lipidology, 2002, Volume: 13, Issue:1 Topics: Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Neoplasms; Risk Assessment; Simvastatin; Venous Thrombosis	2002
Cholesterol inhibition, cancer, and chemotherapy. Lancet (London, England), 1992, May-09, Volume: 339, Issue:8802 Topics: Adjuvants, Pharmaceutic; Animals; Antineoplastic Agents; Cholesterol; Dogs; Drug Evaluation, Preclinical; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Lovastatin; Mevalonic Acid; Mice; Neoplasms; Neoplasms, Experimental; Rats	1992